Attendee search 

Fusion Genomics Corporation (FG) develops molecular diagnostic tests that utilize next-generation sequencing (NGS) technologies. All of FG’s tests can be used with any of the widely adopted NGS instruments on the market. Data is analyzed using FGF’s secure FusionCloud, providing diagnosis –enabling DNA sequence information to the clinician.

Most NGS based diagnostic efforts can be divided into two categories: 1) whole genome sequencing (WGS), where the entire DNA of an individual (or a pathogen) is sequenced, and 2) target-capture sequencing (TCS), where only diseased portions of DNA are sequenced. TCS produces 1000 times less data than WGS. The expensive computational resources required for analysis of WGS data prevents it from being adopted for routine clinical use. Therefore, TCS is more suitable and appealing in frontline diagnostic environments.

TCS uses either PCR or “DNA baits” as the underlying technology to “capture” disease-specific regions of the genome. PCR-based methods suffer from limitations described earlier. FG uses proprietary Quantum ProbesTM, an enhanced form of DNA baits, in all its tests. Quantum ProbesTM allow for nearly limitless expansion of genetic targets and rapid development of new tests as well as patentable techniques that are beyond the capacity of PCR. The superior advantage of Quantum ProbeTM, coupled with FusionCloud analysis and reporting, will drive the successful adoption of the tests. 

The Fusion Genomics team published a very well received peer-reviewed publication which demonstrated that their technology was more sensitive, accurate, rapid and comprehensive than current industry standards such as PCR and FISH.  This study can be found at here.

 $0.5-1M to complete seed round

Founders, board members, family and friends.

Patent applications are pending.

Fusion Genomics Corporation’s team has established expertise in next-generation sequencing, diagnostic test and software development, and information technology.

Mohammed Qadir, PhD., Chief Executive Officer and Chief Scientific Officer has over 17 years of research experience; the last 10 were at the British Columbia Cancer Agency. As part of his early training, he worked with world-renowned experts in genomics and drug development and is the co-inventor of the ChildSeq assay and ChildDecode.

Greg Stazyk, Chief Technical Officer has over 20 years of experience in senior positions in the IT industry. Mr. Stazyk was the IT lead for one of Canada’s largest bioinformatics computing platform at the BC Cancer Agency’s Genome Sciences Centre (GSC). Mr. Stazyk was the senior manager at PMC-Sierra Inc. responsible for its global computer systems operation.

Brian Kwok, VP of Product Development has close to 10 years of experience in molecular biology and genomic technologies including leading edge next-generation sequencing. Mr. Kwok has worked in combinatorial drug screening and led the development of the ChildSeq assay.

Dr. Poul Sorensen MD, PhD: Board member and clinical expert. Dr. Sorensen is a world-renowned pediatric pathologist and is the Johal Chair in Childhood Cancer Research at the University of British Columbia, as well as a professor in the Department of Pathology and a Senior Scientist at the BC Cancer Research Agency (Vancouver, Canada). Dr. Sorensen is also the Chair of the Translational Research committee of the Children’s Oncology Group.